한글목차

오메가 3 처방약의 동향과 예측

세계의 오메가 3 처방약 시장은 2024-2030년의 CAGR이 8.5%로, 2030년까지 추정 48억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 고중성지방혈증, 비만, 심혈관질환(CVD)의 비율 상승, 콜레스테롤치 유지에 대한 의식의 향상으로, 시장 기업은 관련된 의료 문제를 치료하기 위한 혁신적인 의약품 창출에 주력하고 있습니다. 세계의 오메가 3 처방약 시장의 미래는 고중성지방혈증, 고콜레스테롤혈증, 염증성장질환, 류마티스 관절염, 정신질환, 신경 발달 장애 시장의 기회에 의해 유망시되고 있습니다.

오메가 3 처방약 시장 인사이트

Lucintel은 Vascepa가 널리 수용되고 있으므로 예측 기간 중 Vascepa가 최대 부문을 유지할 것으로 예측하고 있습니다.

북미는 심장 관련 질환에 대한 지역적인 불안의 증가에 의해 예측 기간 중에도 최대 지역을 유지할 것으로 예상됩니다.

아래 11개의 주요 질문에 답변하고 있습니다. :

• Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
• Q.2.어느 부문이 보다 빠른 페이스로 성장하는가, 또 이유는?
• Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
• Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
• Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
• Q.6.이 시장에서 새로운 동향과 이유는?
• Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
• Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
• Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
• Q.10.이 시장에서 경쟁 제품은 무엇이며, 재료 및 제품의 대체에 의한 시장 점유율 하락의 위협은 어느 정도인가?
• Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?

목차

제1장 주요 요약

제2장 세계의 오메가 3 처방약 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 2018-2030년의 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 오메가 3 처방약 시장 동향(2018-2023년)과 예측(2024-2030년)
• 의약품별 세계의 오메가 3 처방약 시장
  • Vascepa
  • Lovaza
  • 기타
• 유통 채널별 세계의 오메가 3 처방약 시장
  • 병원 약국
  • 소매 약국
  • 온라인 약국
• 용도별 세계의 오메가 3 처방약 시장
  • 고중성지방혈증
  • 고콜레스테롤
  • 염증성장질환
  • 류마티스 관절염
  • 정신질환
  • 신경 발달 장애
  • 기타

제4장 2018-2030년의 지역별 시장 동향과 예측 분석

• 지역별 세계의 오메가 3 처방약 시장
• 북미의 오메가 3 처방약 시장
• 유럽의 오메가 3 처방약 시장
• 아시아태평양의 오메가 3 처방약 시장
• 기타 지역의 오메가 3 처방약 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 의약품별 세계의 오메가 3 처방약 시장의 성장 기회
  • 유통 채널별 세계의 오메가 3 처방약 시장의 성장 기회
  • 용도별 세계의 오메가 3 처방약 시장의 성장 기회
  • 지역별 세계의 오메가 3 처방약 시장의 성장 기회
• 세계의 오메가 3 처방약 시장의 새로운 동향
• 전략적 분석
  • 신제품의 개발
  • 세계의 오메가 3 처방약 시장의 생산 능력의 확대
  • 세계의 오메가 3 처방약 시장에서의 합병, 인수, 합병사업
  • 인증과 라이선싱

제7장 유력 기업의 기업 개요

• Abbott
• Amarin Pharmaceuticals
• GSK
• Natrapharm
• Viatris
• Grupo Ferrer Internacional
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Zydus
• Hikma Pharmaceuticals

영문목차

Omega 3 Prescription Drug Trends and Forecast

The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets. The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 8.5% from 2024 to 2030. The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

A more than 150-page report is developed to help in your business decisions.

Omega 3 Prescription Drug by Segment

The study includes a forecast for the global omega 3 prescription drug by drug, distribution channel, application, and region.

Omega 3 Prescription Drug Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

• Vascepa
• Lovaza
• Others

Omega 3 Prescription Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Omega 3 Prescription Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Hypertriglyceridemia
• High Cholesterol
• Inflammatory Bowel Disease
• Rheumatoid Arthritis
• Mental Health Conditions
• Neurodevelopmental Disorders
• Others

Omega 3 Prescription Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Omega 3 Prescription Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies omega 3 prescription drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the omega 3 prescription drug companies profiled in this report include-

• Abbott
• Amarin Pharmaceuticals
• GSK
• Natrapharm
• Viatris
• Grupo Ferrer Internacional
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Zydus
• Hikma Pharmaceuticals

Omega 3 Prescription Drug Market Insights

Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Features of the Global Omega 3 Prescription Drug Market

Market Size Estimates: Omega 3 prescription drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Omega 3 prescription drug market size by drug, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Omega 3 prescription drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug, distribution channel, application, and regions for the omega 3 prescription drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the omega 3 prescription drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the omega 3 prescription drug market size?

Answer: The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030.

Q2. What is the growth forecast for omega 3 prescription drug market?

Answer: The global omega 3 prescription drug market is expected to grow with a CAGR of 8.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the omega 3 prescription drug market?

Answer: The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

Q4. What are the major segments for omega 3 prescription drug market?

Answer: The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets.

Q5. Who are the key omega 3 prescription drug market companies?

Answer: Some of the key omega 3 prescription drug companies are as follows:

• Abbott
• Amarin Pharmaceuticals
• GSK
• Natrapharm
• Viatris
• Grupo Ferrer Internacional
• Camber Pharmaceuticals
• Dr. Reddy's Laboratories
• Zydus
• Hikma Pharmaceuticals

Q6. Which omega 3 prescription drug market segment will be the largest in future?

Answer: Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

Q7. In omega 3 prescription drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the omega 3 prescription drug market by drug (vascepa, lovaza, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Omega 3 Prescription Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Omega 3 Prescription Drug Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Omega 3 Prescription Drug Market by Drug
  • 3.3.1: Vascepa
  • 3.3.2: Lovaza
  • 3.3.3: Others
• 3.4: Global Omega 3 Prescription Drug Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Online Pharmacy
• 3.5: Global Omega 3 Prescription Drug Market by Application
  • 3.5.1: Hypertriglyceridemia
  • 3.5.2: High Cholesterol
  • 3.5.3: Inflammatory Bowel Disease
  • 3.5.4: Rheumatoid Arthritis
  • 3.5.5: Mental Health Conditions
  • 3.5.6: Neurodevelopmental Disorders
  • 3.5.7: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Omega 3 Prescription Drug Market by Region
• 4.2: North American Omega 3 Prescription Drug Market
  • 4.2.2: North American Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
• 4.3: European Omega 3 Prescription Drug Market
  • 4.3.1: European Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
  • 4.3.2: European Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
• 4.4: APAC Omega 3 Prescription Drug Market
  • 4.4.1: APAC Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
  • 4.4.2: APAC Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
• 4.5: ROW Omega 3 Prescription Drug Market
  • 4.5.1: ROW Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
  • 4.5.2: ROW Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Drug
  • 6.1.2: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Application
  • 6.1.4: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Region
• 6.2: Emerging Trends in the Global Omega 3 Prescription Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Omega 3 Prescription Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Omega 3 Prescription Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbott
• 7.2: Amarin Pharmaceuticals
• 7.3: GSK
• 7.4: Natrapharm
• 7.5: Viatris
• 7.6: Grupo Ferrer Internacional
• 7.7: Camber Pharmaceuticals
• 7.8: Dr. Reddy's Laboratories
• 7.9: Zydus
• 7.10: Hikma Pharmaceuticals